nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—hematologic cancer	0.477	1	CbGaD
Dolutegravir—UGT1A1—Nilotinib—hematologic cancer	0.092	0.447	CbGbCtD
Dolutegravir—UGT1A1—Irinotecan—hematologic cancer	0.0633	0.307	CbGbCtD
Dolutegravir—UGT1A1—Etoposide—hematologic cancer	0.0507	0.246	CbGbCtD
Dolutegravir—POU2F2—hematopoietic system—hematologic cancer	0.0115	0.271	CbGeAlD
Dolutegravir—POU2F2—blood—hematologic cancer	0.00759	0.18	CbGeAlD
Dolutegravir—POU2F2—lung—hematologic cancer	0.00665	0.157	CbGeAlD
Dolutegravir—POU2F2—BCR signaling pathway—CD22—hematologic cancer	0.0066	0.064	CbGpPWpGaD
Dolutegravir—POU2F2—testis—hematologic cancer	0.00628	0.149	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—GAS2L1—hematologic cancer	0.00489	0.0474	CbGpPWpGaD
Dolutegravir—POU2F2—lymph node—hematologic cancer	0.00455	0.108	CbGeAlD
Dolutegravir—POU2F2—BCR signaling pathway—CD79B—hematologic cancer	0.00426	0.0413	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—GRAMD1B—hematologic cancer	0.0037	0.0359	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MAFB—hematologic cancer	0.0037	0.0359	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—RUNX1—hematologic cancer	0.00349	0.0338	CbGpPWpGaD
Dolutegravir—UGT1A1—hematopoietic system—hematologic cancer	0.00346	0.0818	CbGeAlD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.00336	0.0326	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CEBPD—hematologic cancer	0.00325	0.0315	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—ZBTB16—hematologic cancer	0.00257	0.0249	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—PBX1—hematologic cancer	0.00233	0.0226	CbGpPWpGaD
Dolutegravir—UGT1A1—blood—hematologic cancer	0.00229	0.0542	CbGeAlD
Dolutegravir—POU2F2—Ectoderm Differentiation—TCF3—hematologic cancer	0.00203	0.0197	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—TOP2A—hematologic cancer	0.00201	0.0194	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—CARD11—hematologic cancer	0.0019	0.0184	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—BCL10—hematologic cancer	0.00185	0.018	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MALT1—hematologic cancer	0.00185	0.018	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TCF3—hematologic cancer	0.00184	0.0178	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—hematologic cancer	0.00183	0.0178	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—BTK—hematologic cancer	0.00182	0.0177	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—HDAC10—hematologic cancer	0.00181	0.0175	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—GATA2—hematologic cancer	0.0017	0.0165	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.00164	0.0159	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—RET—hematologic cancer	0.0015	0.0145	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—FHL2—hematologic cancer	0.00147	0.0143	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—SNCA—hematologic cancer	0.00145	0.014	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTPRC—hematologic cancer	0.00144	0.014	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—HES1—hematologic cancer	0.00137	0.0133	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—CD79A—hematologic cancer	0.00126	0.0122	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—SYK—hematologic cancer	0.00126	0.0122	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—GRB2—hematologic cancer	0.00114	0.011	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—ATM—hematologic cancer	0.00108	0.0105	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	0.00106	0.0102	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—TNFRSF11B—hematologic cancer	0.00104	0.0101	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—hematologic cancer	0.00103	0.01	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	0.00102	0.00992	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	0.00101	0.00982	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—MYB—hematologic cancer	0.000975	0.00946	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—ABCG2—hematologic cancer	0.000856	0.0083	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000836	0.00811	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL13—hematologic cancer	0.000834	0.00809	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK14—hematologic cancer	0.000822	0.00797	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—hematologic cancer	0.000822	0.00797	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—MDM2—hematologic cancer	0.000797	0.00773	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—NFKBIA—hematologic cancer	0.000787	0.00763	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—GATA3—hematologic cancer	0.000753	0.0073	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—FOS—hematologic cancer	0.000727	0.00704	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAP2K1—hematologic cancer	0.000674	0.00654	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3R1—hematologic cancer	0.000633	0.00613	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—AR—hematologic cancer	0.000597	0.00579	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—NQO1—hematologic cancer	0.000554	0.00537	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCC3—hematologic cancer	0.000542	0.00526	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HES1—hematologic cancer	0.000525	0.00509	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—hematologic cancer	0.000522	0.00506	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—JUN—hematologic cancer	0.000522	0.00506	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—hematologic cancer	0.000505	0.00489	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK8—hematologic cancer	0.000494	0.00479	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—NR3C1—hematologic cancer	0.000483	0.00468	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—hematologic cancer	0.000431	0.00418	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—hematologic cancer	0.000424	0.00411	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CCL2—hematologic cancer	0.000398	0.00386	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—SMC1A—hematologic cancer	0.000398	0.00386	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUND—hematologic cancer	0.000381	0.0037	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SLC35B2—hematologic cancer	0.000375	0.00363	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CREB1—hematologic cancer	0.000369	0.00358	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6R—hematologic cancer	0.00036	0.00349	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	0.000359	0.00348	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—hematologic cancer	0.000356	0.00345	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—hematologic cancer	0.000329	0.00319	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—HSP90AA1—hematologic cancer	0.000329	0.00319	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—hematologic cancer	0.000291	0.00282	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—hematologic cancer	0.000276	0.00267	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL1B—hematologic cancer	0.000274	0.00265	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—hematologic cancer	0.000273	0.00265	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—JUN—hematologic cancer	0.000265	0.00257	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—hematologic cancer	0.000261	0.00253	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—FOXO1—hematologic cancer	0.000261	0.00253	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HSP90AA1—hematologic cancer	0.000246	0.00238	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EP300—hematologic cancer	0.000245	0.00237	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTO1—hematologic cancer	0.000241	0.00234	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—hematologic cancer	0.000235	0.00228	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	0.000232	0.00225	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—SLC35B2—hematologic cancer	0.000219	0.00212	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—EPHX1—hematologic cancer	0.000216	0.0021	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—hematologic cancer	0.000202	0.00195	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—hematologic cancer	0.000199	0.00193	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—MTR—hematologic cancer	0.000197	0.00191	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—hematologic cancer	0.000195	0.00189	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—hematologic cancer	0.000187	0.00181	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—ABCC3—hematologic cancer	0.000161	0.00156	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TXN—hematologic cancer	0.000161	0.00156	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—hematologic cancer	0.00016	0.00155	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTO1—hematologic cancer	0.000141	0.00137	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTO1—hematologic cancer	0.000139	0.00135	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—hematologic cancer	0.00013	0.00126	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—hematologic cancer	0.000119	0.00116	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—hematologic cancer	0.000118	0.00114	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—MTR—hematologic cancer	0.000115	0.00112	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—hematologic cancer	0.00011	0.00106	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—hematologic cancer	0.000107	0.00104	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—hematologic cancer	0.000105	0.00102	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—hematologic cancer	0.000105	0.00101	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—NQO1—hematologic cancer	0.000104	0.00101	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—hematologic cancer	0.000102	0.000987	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—HSP90AA1—hematologic cancer	9.76e-05	0.000946	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	9.39e-05	0.000911	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	9.14e-05	0.000886	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—hematologic cancer	8.65e-05	0.000839	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	8.17e-05	0.000792	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—HGF—hematologic cancer	7.95e-05	0.000771	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—hematologic cancer	7.95e-05	0.000771	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	7.63e-05	0.000739	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—hematologic cancer	7.59e-05	0.000736	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—hematologic cancer	7.49e-05	0.000726	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—hematologic cancer	6.98e-05	0.000676	CbGpPWpGaD
Dolutegravir—Diarrhoea—Thalidomide—hematologic cancer	6.93e-05	0.000405	CcSEcCtD
Dolutegravir—Dizziness—Thiotepa—hematologic cancer	6.93e-05	0.000405	CcSEcCtD
Dolutegravir—Asthenia—Alitretinoin—hematologic cancer	6.92e-05	0.000404	CcSEcCtD
Dolutegravir—Rash—Vinorelbine—hematologic cancer	6.92e-05	0.000404	CcSEcCtD
Dolutegravir—Dermatitis—Vinorelbine—hematologic cancer	6.91e-05	0.000403	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—hematologic cancer	6.88e-05	0.000667	CbGpPWpGaD
Dolutegravir—Headache—Vinorelbine—hematologic cancer	6.87e-05	0.000401	CcSEcCtD
Dolutegravir—Immune system disorder—Prednisone—hematologic cancer	6.86e-05	0.0004	CcSEcCtD
Dolutegravir—Hypersensitivity—Vincristine—hematologic cancer	6.84e-05	0.0004	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—PDGFB—hematologic cancer	6.84e-05	0.000663	CbGpPWpGaD
Dolutegravir—Asthenia—Ifosfamide—hematologic cancer	6.84e-05	0.000399	CcSEcCtD
Dolutegravir—Pruritus—Alitretinoin—hematologic cancer	6.82e-05	0.000398	CcSEcCtD
Dolutegravir—Vertigo—Dexamethasone—hematologic cancer	6.82e-05	0.000398	CcSEcCtD
Dolutegravir—Vertigo—Betamethasone—hematologic cancer	6.82e-05	0.000398	CcSEcCtD
Dolutegravir—Pruritus—Ifosfamide—hematologic cancer	6.74e-05	0.000394	CcSEcCtD
Dolutegravir—Insomnia—Prednisolone—hematologic cancer	6.71e-05	0.000392	CcSEcCtD
Dolutegravir—Dizziness—Thalidomide—hematologic cancer	6.7e-05	0.000391	CcSEcCtD
Dolutegravir—Hyperglycaemia—Epirubicin—hematologic cancer	6.69e-05	0.000391	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Methotrexate—hematologic cancer	6.68e-05	0.00039	CcSEcCtD
Dolutegravir—Nausea—Bortezomib—hematologic cancer	6.67e-05	0.00039	CcSEcCtD
Dolutegravir—Hypersensitivity—Irinotecan—hematologic cancer	6.67e-05	0.000389	CcSEcCtD
Dolutegravir—Hypersensitivity—Mitoxantrone—hematologic cancer	6.67e-05	0.000389	CcSEcCtD
Dolutegravir—Asthenia—Vincristine—hematologic cancer	6.67e-05	0.000389	CcSEcCtD
Dolutegravir—Vomiting—Thiotepa—hematologic cancer	6.66e-05	0.000389	CcSEcCtD
Dolutegravir—Diarrhoea—Carmustine—hematologic cancer	6.66e-05	0.000389	CcSEcCtD
Dolutegravir—Mental disorder—Prednisone—hematologic cancer	6.65e-05	0.000388	CcSEcCtD
Dolutegravir—Nausea—Bleomycin—hematologic cancer	6.62e-05	0.000387	CcSEcCtD
Dolutegravir—Rash—Thiotepa—hematologic cancer	6.61e-05	0.000386	CcSEcCtD
Dolutegravir—Dermatitis—Thiotepa—hematologic cancer	6.6e-05	0.000385	CcSEcCtD
Dolutegravir—Diarrhoea—Alitretinoin—hematologic cancer	6.6e-05	0.000385	CcSEcCtD
Dolutegravir—Headache—Thiotepa—hematologic cancer	6.56e-05	0.000383	CcSEcCtD
Dolutegravir—Diarrhoea—Ifosfamide—hematologic cancer	6.52e-05	0.000381	CcSEcCtD
Dolutegravir—Nausea—Vinorelbine—hematologic cancer	6.52e-05	0.00038	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—hematologic cancer	6.5e-05	0.00038	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Etoposide—hematologic cancer	6.5e-05	0.000379	CcSEcCtD
Dolutegravir—Asthenia—Irinotecan—hematologic cancer	6.49e-05	0.000379	CcSEcCtD
Dolutegravir—Asthenia—Mitoxantrone—hematologic cancer	6.49e-05	0.000379	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—hematologic cancer	6.49e-05	0.000379	CcSEcCtD
Dolutegravir—Vomiting—Thalidomide—hematologic cancer	6.44e-05	0.000376	CcSEcCtD
Dolutegravir—Dizziness—Carmustine—hematologic cancer	6.44e-05	0.000376	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—hematologic cancer	6.42e-05	0.000375	CcSEcCtD
Dolutegravir—Rash—Thalidomide—hematologic cancer	6.39e-05	0.000373	CcSEcCtD
Dolutegravir—Dermatitis—Thalidomide—hematologic cancer	6.38e-05	0.000373	CcSEcCtD
Dolutegravir—Dizziness—Alitretinoin—hematologic cancer	6.38e-05	0.000372	CcSEcCtD
Dolutegravir—Diarrhoea—Vincristine—hematologic cancer	6.36e-05	0.000371	CcSEcCtD
Dolutegravir—Headache—Thalidomide—hematologic cancer	6.35e-05	0.000371	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—hematologic cancer	6.35e-05	0.00037	CcSEcCtD
Dolutegravir—Asthenia—Gemcitabine—hematologic cancer	6.32e-05	0.000369	CcSEcCtD
Dolutegravir—Dizziness—Ifosfamide—hematologic cancer	6.3e-05	0.000368	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—hematologic cancer	6.27e-05	0.000366	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—hematologic cancer	6.26e-05	0.000365	CcSEcCtD
Dolutegravir—Pruritus—Gemcitabine—hematologic cancer	6.24e-05	0.000364	CcSEcCtD
Dolutegravir—Nausea—Thiotepa—hematologic cancer	6.22e-05	0.000363	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—hematologic cancer	6.22e-05	0.000363	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—hematologic cancer	6.19e-05	0.000362	CcSEcCtD
Dolutegravir—Diarrhoea—Irinotecan—hematologic cancer	6.19e-05	0.000361	CcSEcCtD
Dolutegravir—Diarrhoea—Mitoxantrone—hematologic cancer	6.19e-05	0.000361	CcSEcCtD
Dolutegravir—Vomiting—Carmustine—hematologic cancer	6.19e-05	0.000361	CcSEcCtD
Dolutegravir—Insomnia—Triamcinolone—hematologic cancer	6.17e-05	0.00036	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Etoposide—hematologic cancer	6.15e-05	0.000359	CcSEcCtD
Dolutegravir—Dizziness—Vincristine—hematologic cancer	6.14e-05	0.000359	CcSEcCtD
Dolutegravir—Rash—Carmustine—hematologic cancer	6.14e-05	0.000358	CcSEcCtD
Dolutegravir—Dermatitis—Carmustine—hematologic cancer	6.13e-05	0.000358	CcSEcCtD
Dolutegravir—Vomiting—Alitretinoin—hematologic cancer	6.13e-05	0.000358	CcSEcCtD
Dolutegravir—Headache—Carmustine—hematologic cancer	6.1e-05	0.000356	CcSEcCtD
Dolutegravir—Rash—Alitretinoin—hematologic cancer	6.08e-05	0.000355	CcSEcCtD
Dolutegravir—Nervous system disorder—Betamethasone—hematologic cancer	6.07e-05	0.000355	CcSEcCtD
Dolutegravir—Nervous system disorder—Dexamethasone—hematologic cancer	6.07e-05	0.000355	CcSEcCtD
Dolutegravir—Dermatitis—Alitretinoin—hematologic cancer	6.07e-05	0.000355	CcSEcCtD
Dolutegravir—Vomiting—Ifosfamide—hematologic cancer	6.06e-05	0.000354	CcSEcCtD
Dolutegravir—Hypersensitivity—Cisplatin—hematologic cancer	6.05e-05	0.000353	CcSEcCtD
Dolutegravir—Headache—Alitretinoin—hematologic cancer	6.04e-05	0.000353	CcSEcCtD
Dolutegravir—Diarrhoea—Gemcitabine—hematologic cancer	6.03e-05	0.000352	CcSEcCtD
Dolutegravir—Nausea—Thalidomide—hematologic cancer	6.02e-05	0.000351	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—hematologic cancer	6.02e-05	0.000351	CcSEcCtD
Dolutegravir—Rash—Ifosfamide—hematologic cancer	6.01e-05	0.000351	CcSEcCtD
Dolutegravir—Dermatitis—Ifosfamide—hematologic cancer	6e-05	0.00035	CcSEcCtD
Dolutegravir—Dizziness—Irinotecan—hematologic cancer	5.98e-05	0.000349	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—hematologic cancer	5.95e-05	0.000347	CcSEcCtD
Dolutegravir—Vertigo—Prednisone—hematologic cancer	5.94e-05	0.000347	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—hematologic cancer	5.94e-05	0.000347	CcSEcCtD
Dolutegravir—Vomiting—Vincristine—hematologic cancer	5.91e-05	0.000345	CcSEcCtD
Dolutegravir—Asthenia—Cisplatin—hematologic cancer	5.89e-05	0.000344	CcSEcCtD
Dolutegravir—Fatigue—Triamcinolone—hematologic cancer	5.89e-05	0.000344	CcSEcCtD
Dolutegravir—Urinary tract disorder—Epirubicin—hematologic cancer	5.86e-05	0.000342	CcSEcCtD
Dolutegravir—Rash—Vincristine—hematologic cancer	5.86e-05	0.000342	CcSEcCtD
Dolutegravir—Dermatitis—Vincristine—hematologic cancer	5.85e-05	0.000342	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—hematologic cancer	5.82e-05	0.00034	CcSEcCtD
Dolutegravir—Headache—Vincristine—hematologic cancer	5.82e-05	0.00034	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PHYH—hematologic cancer	5.82e-05	0.000564	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GMPS—hematologic cancer	5.82e-05	0.000564	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FTCD—hematologic cancer	5.82e-05	0.000564	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Doxorubicin—hematologic cancer	5.79e-05	0.000338	CcSEcCtD
Dolutegravir—Nausea—Carmustine—hematologic cancer	5.78e-05	0.000338	CcSEcCtD
Dolutegravir—Vomiting—Mitoxantrone—hematologic cancer	5.75e-05	0.000336	CcSEcCtD
Dolutegravir—Vomiting—Irinotecan—hematologic cancer	5.75e-05	0.000336	CcSEcCtD
Dolutegravir—Immune system disorder—Methotrexate—hematologic cancer	5.73e-05	0.000335	CcSEcCtD
Dolutegravir—Nausea—Alitretinoin—hematologic cancer	5.73e-05	0.000334	CcSEcCtD
Dolutegravir—Rash—Mitoxantrone—hematologic cancer	5.7e-05	0.000333	CcSEcCtD
Dolutegravir—Rash—Irinotecan—hematologic cancer	5.7e-05	0.000333	CcSEcCtD
Dolutegravir—Dermatitis—Irinotecan—hematologic cancer	5.7e-05	0.000333	CcSEcCtD
Dolutegravir—Dermatitis—Mitoxantrone—hematologic cancer	5.7e-05	0.000333	CcSEcCtD
Dolutegravir—Headache—Mitoxantrone—hematologic cancer	5.67e-05	0.000331	CcSEcCtD
Dolutegravir—Headache—Irinotecan—hematologic cancer	5.67e-05	0.000331	CcSEcCtD
Dolutegravir—Nausea—Ifosfamide—hematologic cancer	5.66e-05	0.00033	CcSEcCtD
Dolutegravir—Diarrhoea—Cisplatin—hematologic cancer	5.62e-05	0.000328	CcSEcCtD
Dolutegravir—Vomiting—Gemcitabine—hematologic cancer	5.6e-05	0.000327	CcSEcCtD
Dolutegravir—Insomnia—Dexamethasone—hematologic cancer	5.6e-05	0.000327	CcSEcCtD
Dolutegravir—Insomnia—Betamethasone—hematologic cancer	5.6e-05	0.000327	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	5.59e-05	0.000326	CcSEcCtD
Dolutegravir—Mental disorder—Methotrexate—hematologic cancer	5.56e-05	0.000325	CcSEcCtD
Dolutegravir—Rash—Gemcitabine—hematologic cancer	5.56e-05	0.000324	CcSEcCtD
Dolutegravir—Dermatitis—Gemcitabine—hematologic cancer	5.55e-05	0.000324	CcSEcCtD
Dolutegravir—Hypersensitivity—Etoposide—hematologic cancer	5.54e-05	0.000324	CcSEcCtD
Dolutegravir—Headache—Gemcitabine—hematologic cancer	5.52e-05	0.000322	CcSEcCtD
Dolutegravir—Nausea—Vincristine—hematologic cancer	5.52e-05	0.000322	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—hematologic cancer	5.49e-05	0.000321	CcSEcCtD
Dolutegravir—Hypersensitivity—Prednisolone—hematologic cancer	5.47e-05	0.000319	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—hematologic cancer	5.43e-05	0.000317	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—hematologic cancer	5.4e-05	0.000315	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—hematologic cancer	5.39e-05	0.000314	CcSEcCtD
Dolutegravir—Nausea—Mitoxantrone—hematologic cancer	5.37e-05	0.000314	CcSEcCtD
Dolutegravir—Nausea—Irinotecan—hematologic cancer	5.37e-05	0.000314	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—hematologic cancer	5.36e-05	0.000313	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.35e-05	0.000312	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.35e-05	0.000312	CcSEcCtD
Dolutegravir—Fatigue—Betamethasone—hematologic cancer	5.34e-05	0.000312	CcSEcCtD
Dolutegravir—Fatigue—Dexamethasone—hematologic cancer	5.34e-05	0.000312	CcSEcCtD
Dolutegravir—Pruritus—Etoposide—hematologic cancer	5.32e-05	0.000311	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SMPD3—hematologic cancer	5.32e-05	0.000516	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Prednisone—hematologic cancer	5.29e-05	0.000309	CcSEcCtD
Dolutegravir—Skin disorder—Prednisone—hematologic cancer	5.24e-05	0.000306	CcSEcCtD
Dolutegravir—Nausea—Gemcitabine—hematologic cancer	5.24e-05	0.000306	CcSEcCtD
Dolutegravir—Vomiting—Cisplatin—hematologic cancer	5.22e-05	0.000305	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—hematologic cancer	5.2e-05	0.000304	CcSEcCtD
Dolutegravir—Rash—Cisplatin—hematologic cancer	5.18e-05	0.000302	CcSEcCtD
Dolutegravir—Dermatitis—Cisplatin—hematologic cancer	5.17e-05	0.000302	CcSEcCtD
Dolutegravir—Diarrhoea—Etoposide—hematologic cancer	5.15e-05	0.000301	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—hematologic cancer	5.09e-05	0.000297	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Betamethasone—hematologic cancer	5.06e-05	0.000296	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.06e-05	0.000296	CcSEcCtD
Dolutegravir—Hypersensitivity—Triamcinolone—hematologic cancer	5.03e-05	0.000294	CcSEcCtD
Dolutegravir—Dizziness—Etoposide—hematologic cancer	4.98e-05	0.000291	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—hematologic cancer	4.96e-05	0.00029	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—hematologic cancer	4.96e-05	0.00029	CcSEcCtD
Dolutegravir—Dizziness—Prednisolone—hematologic cancer	4.91e-05	0.000287	CcSEcCtD
Dolutegravir—Asthenia—Triamcinolone—hematologic cancer	4.9e-05	0.000286	CcSEcCtD
Dolutegravir—Abdominal pain—Dexamethasone—hematologic cancer	4.9e-05	0.000286	CcSEcCtD
Dolutegravir—Abdominal pain—Betamethasone—hematologic cancer	4.9e-05	0.000286	CcSEcCtD
Dolutegravir—Nausea—Cisplatin—hematologic cancer	4.88e-05	0.000285	CcSEcCtD
Dolutegravir—Insomnia—Prednisone—hematologic cancer	4.88e-05	0.000285	CcSEcCtD
Dolutegravir—Pruritus—Triamcinolone—hematologic cancer	4.83e-05	0.000282	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—hematologic cancer	4.81e-05	0.000281	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—hematologic cancer	4.79e-05	0.000279	CcSEcCtD
Dolutegravir—Rash—Etoposide—hematologic cancer	4.75e-05	0.000277	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—hematologic cancer	4.74e-05	0.000277	CcSEcCtD
Dolutegravir—Headache—Etoposide—hematologic cancer	4.71e-05	0.000275	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—hematologic cancer	4.71e-05	0.000275	CcSEcCtD
Dolutegravir—Rash—Prednisolone—hematologic cancer	4.68e-05	0.000273	CcSEcCtD
Dolutegravir—Dermatitis—Prednisolone—hematologic cancer	4.68e-05	0.000273	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	4.67e-05	0.000273	CcSEcCtD
Dolutegravir—Fatigue—Prednisone—hematologic cancer	4.65e-05	0.000272	CcSEcCtD
Dolutegravir—Headache—Prednisolone—hematologic cancer	4.65e-05	0.000272	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—B3GAT1—hematologic cancer	4.65e-05	0.000451	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ASNS—hematologic cancer	4.65e-05	0.000451	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DCK—hematologic cancer	4.65e-05	0.000451	CbGpPWpGaD
Dolutegravir—Vertigo—Epirubicin—hematologic cancer	4.64e-05	0.000271	CcSEcCtD
Dolutegravir—Dizziness—Triamcinolone—hematologic cancer	4.51e-05	0.000264	CcSEcCtD
Dolutegravir—Nausea—Etoposide—hematologic cancer	4.47e-05	0.000261	CcSEcCtD
Dolutegravir—Asthenia—Dexamethasone—hematologic cancer	4.44e-05	0.000259	CcSEcCtD
Dolutegravir—Asthenia—Betamethasone—hematologic cancer	4.44e-05	0.000259	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—hematologic cancer	4.42e-05	0.000258	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Prednisone—hematologic cancer	4.41e-05	0.000258	CcSEcCtD
Dolutegravir—Nausea—Prednisolone—hematologic cancer	4.41e-05	0.000257	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HDC—hematologic cancer	4.41e-05	0.000427	CbGpPWpGaD
Dolutegravir—Pruritus—Betamethasone—hematologic cancer	4.38e-05	0.000256	CcSEcCtD
Dolutegravir—Pruritus—Dexamethasone—hematologic cancer	4.38e-05	0.000256	CcSEcCtD
Dolutegravir—Skin disorder—Methotrexate—hematologic cancer	4.38e-05	0.000256	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.37e-05	0.000255	CcSEcCtD
Dolutegravir—Vomiting—Triamcinolone—hematologic cancer	4.34e-05	0.000253	CcSEcCtD
Dolutegravir—Rash—Triamcinolone—hematologic cancer	4.3e-05	0.000251	CcSEcCtD
Dolutegravir—Dermatitis—Triamcinolone—hematologic cancer	4.3e-05	0.000251	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—hematologic cancer	4.3e-05	0.000251	CcSEcCtD
Dolutegravir—Headache—Triamcinolone—hematologic cancer	4.28e-05	0.00025	CcSEcCtD
Dolutegravir—Abdominal pain—Prednisone—hematologic cancer	4.26e-05	0.000249	CcSEcCtD
Dolutegravir—Diarrhoea—Betamethasone—hematologic cancer	4.24e-05	0.000247	CcSEcCtD
Dolutegravir—Diarrhoea—Dexamethasone—hematologic cancer	4.24e-05	0.000247	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—hematologic cancer	4.14e-05	0.000242	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—hematologic cancer	4.1e-05	0.000239	CcSEcCtD
Dolutegravir—Dizziness—Dexamethasone—hematologic cancer	4.1e-05	0.000239	CcSEcCtD
Dolutegravir—Dizziness—Betamethasone—hematologic cancer	4.1e-05	0.000239	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—hematologic cancer	4.08e-05	0.000238	CcSEcCtD
Dolutegravir—Nausea—Triamcinolone—hematologic cancer	4.05e-05	0.000237	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.04e-05	0.000236	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CDA—hematologic cancer	4.03e-05	0.000391	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Prednisone—hematologic cancer	3.97e-05	0.000232	CcSEcCtD
Dolutegravir—Vomiting—Betamethasone—hematologic cancer	3.94e-05	0.00023	CcSEcCtD
Dolutegravir—Vomiting—Dexamethasone—hematologic cancer	3.94e-05	0.00023	CcSEcCtD
Dolutegravir—Rash—Dexamethasone—hematologic cancer	3.91e-05	0.000228	CcSEcCtD
Dolutegravir—Rash—Betamethasone—hematologic cancer	3.91e-05	0.000228	CcSEcCtD
Dolutegravir—Dermatitis—Betamethasone—hematologic cancer	3.9e-05	0.000228	CcSEcCtD
Dolutegravir—Dermatitis—Dexamethasone—hematologic cancer	3.9e-05	0.000228	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—hematologic cancer	3.89e-05	0.000227	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—hematologic cancer	3.89e-05	0.000227	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—PC—hematologic cancer	3.88e-05	0.000376	CbGpPWpGaD
Dolutegravir—Headache—Dexamethasone—hematologic cancer	3.88e-05	0.000227	CcSEcCtD
Dolutegravir—Headache—Betamethasone—hematologic cancer	3.88e-05	0.000227	CcSEcCtD
Dolutegravir—Asthenia—Prednisone—hematologic cancer	3.87e-05	0.000226	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—hematologic cancer	3.83e-05	0.000224	CcSEcCtD
Dolutegravir—Pruritus—Prednisone—hematologic cancer	3.82e-05	0.000223	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—hematologic cancer	3.82e-05	0.000223	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—hematologic cancer	3.79e-05	0.000221	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—GBA—hematologic cancer	3.75e-05	0.000363	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC35B2—hematologic cancer	3.75e-05	0.000363	CbGpPWpGaD
Dolutegravir—Diarrhoea—Prednisone—hematologic cancer	3.69e-05	0.000215	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—hematologic cancer	3.69e-05	0.000215	CcSEcCtD
Dolutegravir—Nausea—Dexamethasone—hematologic cancer	3.68e-05	0.000215	CcSEcCtD
Dolutegravir—Nausea—Betamethasone—hematologic cancer	3.68e-05	0.000215	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.64e-05	0.000213	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—hematologic cancer	3.64e-05	0.000212	CcSEcCtD
Dolutegravir—Dizziness—Prednisone—hematologic cancer	3.57e-05	0.000208	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—hematologic cancer	3.56e-05	0.000208	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—hematologic cancer	3.53e-05	0.000206	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Epirubicin—hematologic cancer	3.45e-05	0.000201	CcSEcCtD
Dolutegravir—Vomiting—Prednisone—hematologic cancer	3.43e-05	0.0002	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—MTAP—hematologic cancer	3.43e-05	0.000332	CbGpPWpGaD
Dolutegravir—Rash—Prednisone—hematologic cancer	3.4e-05	0.000199	CcSEcCtD
Dolutegravir—Dermatitis—Prednisone—hematologic cancer	3.4e-05	0.000198	CcSEcCtD
Dolutegravir—Headache—Prednisone—hematologic cancer	3.38e-05	0.000197	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.37e-05	0.000197	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—hematologic cancer	3.37e-05	0.000196	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—hematologic cancer	3.33e-05	0.000195	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—hematologic cancer	3.32e-05	0.000194	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB1—hematologic cancer	3.24e-05	0.000314	CbGpPWpGaD
Dolutegravir—Asthenia—Methotrexate—hematologic cancer	3.23e-05	0.000189	CcSEcCtD
Dolutegravir—Nausea—Prednisone—hematologic cancer	3.2e-05	0.000187	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.19e-05	0.000186	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—hematologic cancer	3.19e-05	0.000186	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—hematologic cancer	3.11e-05	0.000181	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—hematologic cancer	3.09e-05	0.00018	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—hematologic cancer	3.08e-05	0.00018	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—FHL2—hematologic cancer	3.06e-05	0.000296	CbGpPWpGaD
Dolutegravir—Asthenia—Epirubicin—hematologic cancer	3.03e-05	0.000177	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—AGRN—hematologic cancer	3e-05	0.000291	CbGpPWpGaD
Dolutegravir—Pruritus—Epirubicin—hematologic cancer	2.98e-05	0.000174	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—hematologic cancer	2.98e-05	0.000174	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—hematologic cancer	2.89e-05	0.000169	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—hematologic cancer	2.88e-05	0.000168	CcSEcCtD
Dolutegravir—Vomiting—Methotrexate—hematologic cancer	2.87e-05	0.000167	CcSEcCtD
Dolutegravir—Rash—Methotrexate—hematologic cancer	2.84e-05	0.000166	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—IDH2—hematologic cancer	2.84e-05	0.000275	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HMMR—hematologic cancer	2.84e-05	0.000275	CbGpPWpGaD
Dolutegravir—Dermatitis—Methotrexate—hematologic cancer	2.84e-05	0.000166	CcSEcCtD
Dolutegravir—Headache—Methotrexate—hematologic cancer	2.82e-05	0.000165	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—hematologic cancer	2.8e-05	0.000164	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—hematologic cancer	2.79e-05	0.000163	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—hematologic cancer	2.76e-05	0.000161	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—hematologic cancer	2.68e-05	0.000157	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—hematologic cancer	2.68e-05	0.000156	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ARNTL—hematologic cancer	2.67e-05	0.000259	CbGpPWpGaD
Dolutegravir—Diarrhoea—Doxorubicin—hematologic cancer	2.67e-05	0.000156	CcSEcCtD
Dolutegravir—Rash—Epirubicin—hematologic cancer	2.66e-05	0.000155	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—hematologic cancer	2.66e-05	0.000155	CcSEcCtD
Dolutegravir—Headache—Epirubicin—hematologic cancer	2.64e-05	0.000154	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ACP5—hematologic cancer	2.6e-05	0.000252	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CA9—hematologic cancer	2.6e-05	0.000252	CbGpPWpGaD
Dolutegravir—Dizziness—Doxorubicin—hematologic cancer	2.58e-05	0.000151	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—NCOR2—hematologic cancer	2.56e-05	0.000249	CbGpPWpGaD
Dolutegravir—Nausea—Epirubicin—hematologic cancer	2.51e-05	0.000146	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—hematologic cancer	2.48e-05	0.000145	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—hematologic cancer	2.46e-05	0.000144	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—hematologic cancer	2.46e-05	0.000144	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—hematologic cancer	2.45e-05	0.000143	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—IDH1—hematologic cancer	2.44e-05	0.000237	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCC3—hematologic cancer	2.42e-05	0.000234	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TXN—hematologic cancer	2.42e-05	0.000234	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTO1—hematologic cancer	2.42e-05	0.000234	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SPHK1—hematologic cancer	2.36e-05	0.000229	CbGpPWpGaD
Dolutegravir—Nausea—Doxorubicin—hematologic cancer	2.32e-05	0.000135	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SLC22A1—hematologic cancer	2.21e-05	0.000214	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CRABP1—hematologic cancer	2.21e-05	0.000214	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALOX5—hematologic cancer	2.15e-05	0.000209	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NUP98—hematologic cancer	2.08e-05	0.000202	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ADCY7—hematologic cancer	2.02e-05	0.000196	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA3—hematologic cancer	2.02e-05	0.000196	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NUP214—hematologic cancer	2.01e-05	0.000195	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTR—hematologic cancer	1.97e-05	0.000191	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCG2—hematologic cancer	1.97e-05	0.000191	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ENO2—hematologic cancer	1.93e-05	0.000187	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—hematologic cancer	1.87e-05	0.000182	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SDC1—hematologic cancer	1.83e-05	0.000177	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NQO1—hematologic cancer	1.56e-05	0.000151	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CD44—hematologic cancer	1.56e-05	0.000151	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYCS—hematologic cancer	1.47e-05	0.000143	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HSP90AA1—hematologic cancer	1.46e-05	0.000142	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—hematologic cancer	1.3e-05	0.000126	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCB1—hematologic cancer	1.23e-05	0.000119	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—hematologic cancer	1.19e-05	0.000116	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOR1—hematologic cancer	1.19e-05	0.000116	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTHFR—hematologic cancer	1.05e-05	0.000102	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—hematologic cancer	8.86e-06	8.59e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CREBBP—hematologic cancer	8.21e-06	7.96e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—hematologic cancer	7.79e-06	7.55e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—hematologic cancer	7.69e-06	7.45e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3R1—hematologic cancer	7.35e-06	7.13e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—hematologic cancer	6.79e-06	6.58e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—hematologic cancer	5.87e-06	5.69e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—EP300—hematologic cancer	5.59e-06	5.42e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—hematologic cancer	4.14e-06	4.01e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—hematologic cancer	3.38e-06	3.28e-05	CbGpPWpGaD
